Phesgo logo
WebSelect patients for therapy based on an FDA-approved companion diagnostic test. PHESGO TM is indicated for use in combination with docetaxel for the treatment of adult patients … WebOct 13, 2024 · Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a combination of HER2 /neu receptor antagonists and an endoglycosidase indicated for use in combination with chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2cm in diameter …
Phesgo logo
Did you know?
WebOct 13, 2024 · PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection is a sterile, preservative-free, clear to opalescent, and colorless to slightly brownish solution … WebThank you for visiting our site. You are about to leave the site to one that is not affiliated to Roche Products (New Zealand) Ltd. Roche Products (New Zealand) does not endorse or control, the content of any linked websites and if you click OK, you agree that Roche has no responsibility or duty to you for anything that happens to you as a result.
WebPHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) My Patient Solutions® Login Log in to My Patient Solutions® Call (877) 436-3683 Call (877) 436-3683 WebNov 30, 2024 · loss of consciousness. lower back, side, or stomach pain. mood or mental changes. muscle twitching. pinpoint red spots on the skin. severe sleepiness. stomach cramps. tremor. unusual drowsiness, dullness, or feeling of sluggishness.
WebWith the Genentech Oncology Co-pay Assistance Program, eligible patients with commercial insurance could pay as little as $5 per treatment for PHESGO. Co-pay assistance of up to $25,000 is provided per calendar year. Are over the age of 18, or have a Legally Authorized Person over the age of 18 to manage the program. WebJun 29, 2024 · SAN DIEGO, June 29, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has approved Roche's Phesgo™ (pertuzumab,...
WebJan 1, 2024 · Phesgo 600 mg/600 mg/20,000 units (providing 600 mg pertuzumab, 600 mg trastuzumab and 20,000 units hyaluronidase per 10 mL) single-dose vials: 50242-0260-xx VII. References 1. Phesgo [package insert]. South San Francisco, CA; Genentech, Inc; June 2024. Accessed August 2024. 2.
WebJun 29, 2024 · The safety profile of PHESGO is comparable to intravenous pertuzumab and trastuzumab, except for increased administration-related reactions. The most common adverse reactions in >30% patients... tmnt 2003 ultimate ninjaWebPhesgo is a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two ... tmnt 2014 dr. john o\u0027neilWeb600 mg pertuzumab, 600 mg trastuzumab, 20,000 units hyaluronidase per 10 mL supplied in a single-dose, ready-to-use vial. Administer subcutaneously over approximately 5 minutes at a rate of no more than 2 mL/min. Observe for hypersensitivity or administration-related reactions: minimum of 15 minutes*. NDC: 50242-260-01. tmnt 2012 oroku keijiWebPhesgo is a combination medication containing pertuzumab, trastuzumab, and hyaluronidase or hyaluronidase-zzxf. It's a targeted anticancer treatment for HER2-positive breast cancer that’s either in the early or metastatic stage. Phesgo is an injection that’s given under the skin, and it’s typically used along with other chemotherapy. tmnt 2 ninja rapWebAug 8, 2024 · Phesgo is a cancer medicine that is used alone or with other medicines to treat early-stage breast cancer. Phesgo is also used to treat HER2-positive breast cancer that is advanced or has spread to other parts of the body (metastatic). Phesgo is used for breast cancer only if your tumor tests positive for a protein called human epidermal … tmnt crtani na srpskomWebPHESGO is a prescription medicine approved for use in combination with docetaxel in adults who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer. What are the most serious side effects of PHESGO? tmnt 2012 super ninjaWebPHESGO may cause serious lung problems. Your doctor may check for signs of lung problems including: Severe shortness of breath Fluid in or around the lungs Weakening of the valve between the heart and the lungs Not enough oxygen in the body Swelling of the lungs Scarring of the lungs Who should not receive PHESGO? tmnt blu ray pizza box